Emtricitabine and Reyataz drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Emtricitabine (emtricitabine) and Reyataz (atazanavir sulfate). Common drug interactions include cervix carcinoma among females and alanine aminotransferase increased among males.

The phase IV clinical study analyzes what interactions people have when they take Emtricitabine and Reyataz. It is created by eHealthMe based on reports of 95 people who take the same drugs from the FDA, and is updated regularly.

What is Emtricitabine?

Emtricitabine has active ingredients of emtricitabine. eHealthMe is studying from 6,391 Emtricitabine users. Check the latest studies of Emtricitabine.

What is Reyataz?

Reyataz has active ingredients of atazanavir sulfate. It is often used in hiv infection. eHealthMe is studying from 11,386 Reyataz users. Check the latest studies of Reyataz.

On Jul, 15, 2026

95 people who take Emtricitabine and Reyataz together, and have interactions are studied.

Emtricitabine and Reyataz drug interactions.

What are the common drug interactions of Emtricitabine and Reyataz, by gender? *:

female:

Cervix carcinoma (cancer of cervix)
Death
Low birth weight baby
Metabolic acidosis (body produces too much acid, or when the kidneys are not removing enough acid from the body)
Overdose
Pre-eclampsia (high blood pressure and significant amounts of protein in the urine of a pregnant woman)
Renal impairment (severely reduced kidney function)
Stillbirth (a birth of dead foetus)
Abdominal discomfort
Abortion spontaneous (naturally occurring miscarriage)

male:

Alanine aminotransferase increased
Anaemia (lack of blood)
Nasopharyngitis (inflammation of the nasopharynx)
Oral herpes (viral infection of mouth)
Pruritus (severe itching of the skin)
Restlessness (not able to rest)
Sinusitis (inflammation of sinus)
Skin irritation
Vertigo
Withdrawal syndrome (a discontinuation syndrome is a set of symptoms occurred due to discontinuation of substance)

What are the common drug interactions of Emtricitabine and Reyataz, by age (0-1 to 60+)? *:

0-1:

Foetal exposure during pregnancy (exposing your unborn child to contraindicated in pregnancy leads birth defect)
Premature baby
Foetal death (death of foetus)
Single functional kidney (single kidney)
Foetal exposure during delivery (exposing your unborn child to contraindicated in pregnancy leads birth defect)
Hydrocephalus (water on the brain)
Low birth weight baby
Cerebral haemorrhage neonatal (bleeding in brain of baby of less than 1 month age)
Cytogenetic abnormality
Hyperbilirubinaemia neonatal (excess of bilirubin in the blood in newborn)

2-9:

n/a

10-19:

n/a

20-29:

Vomiting
Anxiety
Overdose
Pre-eclampsia (high blood pressure and significant amounts of protein in the urine of a pregnant woman)
Stillbirth (a birth of dead foetus)
Blood pressure decreased
Diarrhoea
Eyelid oedema (eyelids are swollen and contain excessive fluid)
Maternal exposure during pregnancy (use of substance during pregnancy)
Peripheral swelling

30-39:

Alanine aminotransferase increased
Anaemia (lack of blood)
Depressed mood
Dizziness
Dry skin
Fatigue (feeling of tiredness)
Headache (pain in head)
Impaired healing
Influenza like illness
Nasopharyngitis (inflammation of the nasopharynx)

40-49:

Nausea (feeling of having an urge to vomit)
Overdose
Pain
Polyneuropathy (neurological disorder that occurs when many peripheral nerves throughout the body malfunction simultaneously)
Pyrexia (fever)
Rash
Rash macular (small, flat red spots)
Urinary tract disorder
Viral load increased
Vomiting

50-59:

Cardiac failure congestive
Cardiomyopathy (weakening of the heart muscle)
Hepatic encephalopathy (spectrum of neuropsychiatric abnormalities in patients with liver failure)
Hepatic failure (liver failure)
Loss of consciousness
Seizure (abnormal excessive or synchronous neuronal activity in the brain)
Ascites (accumulation of fluid in the abdominal cavity)
Chronic kidney disease
Dermatitis (inflammation of the skin resulting from direct irritation by an external agent or an allergic reaction to it)
Drug resistance (reduction in effectiveness of a drug)

60+:

Bone density decreased
Emotional distress
Depression
Osteonecrosis (death of bone)
Osteopenia (a condition where bone mineral density is lower than normal)
Osteoporosis (bones weak and more likely to break)
Post-traumatic stress disorder
Spinal compression fracture (fracture due to spinal compression on bone)
Renal failure (kidney dysfunction)
Vomiting

What are the existing conditions these people have? *

Pain: 8 people, 8.42%
Hepatitis C: 8 people, 8.42%
High Blood Pressure: 7 people, 7.37%
Hypersensitivity: 6 people, 6.32%
Headache (pain in head): 6 people, 6.32%
Diarrhea: 6 people, 6.32%

* Approximation only. Some reports may have incomplete information.

Do you take Emtricitabine and Reyataz?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously